Uysal Z, Bakkaloğlu M
Department of Urology, University of Hacettepe, School of Medicine, Sihhiye, Ankara, Turkey.
Int Urol Nephrol. 1987;19(4):415-8. doi: 10.1007/BF02550358.
Radioimmunoassay (RIA) determinations of serum alphafetoprotein (AFP), beta human chorionic gonadotropin (BHCG) and estradiol (E2) levels have been made at various stages of the disease in 52 patients with testicular carcinoma. In non-seminomatous tumours of the testis, E2 has been found to be a highly specific tumour marker, helping to reduce clinical staging error. Increases in serum E2 levels have been observed in all patients with HCG-secreting tumours, but E2 has indicated tumour recurrence alone in 4 patients with normal AFP and BHCG levels. Gynecomastia, always accompanied by a rise in serum E2 and BHCG levels has been a bad prognostic sign. E2 had no significance as a marker in seminomatous tumours.
对52例睾丸癌患者在疾病的不同阶段进行了血清甲胎蛋白（AFP）、人绒毛膜促性腺激素β亚基（β-HCG）和雌二醇（E2）水平的放射免疫分析（RIA）测定。在睾丸非精原细胞瘤中，E2被发现是一种高度特异性的肿瘤标志物，有助于减少临床分期误差。在所有分泌HCG的肿瘤患者中均观察到血清E2水平升高，但在4例AFP和β-HCG水平正常的患者中，E2单独提示肿瘤复发。男性乳房发育总是伴随着血清E2和β-HCG水平升高，一直是预后不良的征象。E2作为精原细胞瘤的标志物无意义。
